Table 1.

Summary of the research phase of the mTOR inhibitors

mTOR inhibitors	Applied tumor	Phase	References
Everolimus	RCC	FDA approved	–
Temsirolimus	Advanced RCC	FDA approved	–
ICSN3250	Colon cancer cell	Pre-clinical studies	Nguyen et al. [53]
LY3023414	Solid tumor or lymphoma	Phase I clinical trial	Bendell et al. [54]
OSU-53	Thyroid cancer cell	Pre-clinical studies	Plews et al. [55]
AZD8055	OCCC cell	Pre-clinical studies	Caumanns et al. [59]
Everolimus	Aggressive and RAIR thyroid cancer	Phase II clinical trial	Hanna et al. [60]
Rapamycin	Pancreatic cancer	Pre-clinical studies	Morran et al. [61]
Temsirolimus	PCNSL	Phase II clinical trial	Korfel et al. [62]

RCC renal cell carcinoma, OCCC ovarian clear cell carcinoma, RAIR radioactive iodine-refractory, PCNSL primary central nervous system lymphoma, FDA Food and Drug Administration